Corrigendum: Dynamic evolution of left ventricular strain and microvascular perfusion assessed by speckle tracking echocardiography and myocardial contrast echocardiography in diabetic rats: effect of dapagliflozin.
更正：糖尿病大鼠左心室應變和微血管灌注的動態演變，通過斑點追蹤超聲心動圖和心肌對比超聲心動圖評估：dapagliflozin 的影響。
Front Cardiovasc Med 2024-07-24
Corrigendum to "The Association Between Metabolic Syndrome, Hyperfiltration, and Long-Term GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 9, September 2023, Pages 1831-1840].
對於「代謝症候群、高過濾率與一般人群長期GFR下降之間的關聯」的更正 [<i>Kidney International Reports</i> 第8卷，第9期，2023年9月，頁1831-1840]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1267 EMPAGLIFLOZIN IMPROVES VITALITY AND PROTECT FROM ADVANCED GLYCATION END PRODUCTS IN ENDOTHELIAL CELLS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S637].
對於「WCN24-1267 EMPAGLIFLOZIN 改善活力並保護內皮細胞免受高級糖化終產物的影響」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S637頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S368-S369].
對於「WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S368-S369]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是其他相關的問題，請提供更多細節！
PubMedDOI
Corrigendum to "WCN24-813 MANAGEMENT OF ACUTE FLUID OVERLOAD IN HEART FAILURE PATIENTS WITH CKD USING HOME DELIVERED SUBCUTANEOUS FUROSEMIDE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S251-S252].
對於「WCN24-813 心衰竭合併慢性腎病患者急性液體過載的管理：使用居家配送的皮下注射 Furosemide」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S251-S252]。
Kidney Int Rep 2024-09-18
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是其他相關的問題，請提供更多細節！
PubMedDOI
Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. <i>J. Cardiovasc. Dev. Dis.</i> 2024, <i>11</i>, 182.
Balleza Alejandri 等人。Empagliflozin 和 Dapagliflozin 改善墨西哥 2 型糖尿病患者的內皮功能：一項雙盲臨床試驗。<i>J. Cardiovasc. Dev. Dis.</i> 2024, <i>11</i>, 182。
J Cardiovasc Dev Dis 2024-10-25
Corrigendum to "Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism".
對於「Empagliflozin 改善肥胖小鼠的主動脈損傷，通過調節脂肪酸代謝」的更正。
Open Med (Wars) 2025-02-24
Corrigendum to "Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia" [<i>Kidney International Reports</i> Volume 9, Issue 5, May 2024, Pages 1419-1428].
對於「Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia」的更正 [<i>Kidney International Reports</i> 第9卷，第5期，2024年5月，頁1419-1428]。
Kidney Int Rep 2025-02-24
Corrigendum: Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts.
更正：dapagliflozin 和 empagliflozin 在孤立兔心臟中對心室和心房心動過速的不同電生理作用。
Front Cardiovasc Med 2025-03-11